Drug Trial Radar · NCT02583373
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
Last checked: Nov 19, 2026Latest source record: Jan 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Mar 21, 2016
Primary completion
Feb 20, 2018
Study completion Feb 20, 2018
Sponsor
- Lead sponsor
- Combioxin SAIndustry
- Sponsor type
- Industry
- First posted
- Oct 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous administration of CAL02 in addition of standard of care antibiotic treatment.
Conditions
- Pneumonia
- Pneumococcal Infections
Interventions
CAL02 Low-doseDrug
Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
CAL02 High-doseDrug
Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
PlaceboDrug
Placebo administered administered 2 times (24 hours apart) as i.v. infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency, severity and characteristics of adverse events after two iv. administrations of CAL02.Time frame: 29 days
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
St Luc University Hospital
Brussels, Belgium
University Hospital Brussels
Brussels, Belgium
Clinique St Pierre
Ottignies, Belgium
CHU Jean Minjoz
Besançon, France
CHD Les Oudairies
La Roche-sur-Yon, France
Hôpital Mignot
Le Chesnay, France
CHU Dupuytren
Limoges, France
Centre Hospitalier Régional d'ORLEANS
Orléans, France
CH Yves Le Foll
Saint-Brieuc, France
CHRU de Tours
Tours, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.